Zoetis (NYSE:ZTS) (NYSE: ZTS) is a global animal health company dedicated to discovering, developing, manufacturing and commercializing a broad portfolio of veterinary medicines, vaccines and diagnostic products. Created as a spin-off from Pfizer in 2013, Zoetis has built a leadership position in animal health by focusing on science-based research and innovation. Its product range addresses the needs of both livestock producers—covering cattle, swine, poultry and aquaculture—and companion animal owners, with solutions for dogs, cats and horses.
The company’s offerings include anti-infective, anti-inflammatory and pain management therapies as well as parasiticides, vaccines and reproductive health products for farm and ranch animals. For companion animals, Zoetis provides prescription treatments for conditions such as arthritis, cancer and dermatology, alongside routine vaccines and parasiticides designed to protect against fleas, ticks and heartworm. The integration of diagnostics, such as rapid tests and instrument-based platforms, enables veterinarians to make timely, data-driven decisions at the point of care.
With operations in more than 100 countries and manufacturing facilities across North America, Europe, Latin America and the Asia-Pacific region, Zoetis serves a diverse customer base that includes veterinarians, livestock producers and distributors. The company’s global reach is supported by research centers in the United States and Europe, driving the development of novel therapies and technology platforms that meet regional and species-specific needs.
Under the leadership of President and Chief Executive Officer Kristin Peck, Zoetis continues to pursue strategic acquisitions and collaborations to expand its product portfolio and geographic footprint. The company’s commitment to advancing animal health and welfare is underpinned by ongoing investments in R&D, aimed at delivering sustainable solutions that benefit animals, their owners and the broader agricultural community.
